Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - Taiwan Liposome Company

Next Previous
Drug Profile

Doxorubicin liposomal - Taiwan Liposome Company

Alternative Names: Doxolipad; Lipo-Dox; TLC 177

Latest Information Update: 31 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiwan Liposome Company
  • Developer Chang Gung Memorial Hospital; Taiwan Liposome Company; TTY Biopharm
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Kaposi's sarcoma; Ovarian cancer
  • Phase II HER2 negative breast cancer

Most Recent Events

  • 09 Sep 2022 Initial efficacy and adverse events data from a phase II trial in Breast cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 11 Mar 2021 No development reported - Phase-III for Ovarian cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, India (IV)
  • 29 May 2019 The Committee for Medicinal Products for Human Use (CHMP) confirms the adoption of negative opinion for MAA after re-examination for doxorubicin liposomal for Breast cancer and Ovarian cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top